Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04296-8 Early clinical data on in vivo CAR-T cell …
Tag:
Cancer immunotherapy
-
-
Competing interests D.D. has been a member of the data and safety monitoring board, the independent …
-
Competing interests No author has received financial support for the work on this paper, and no …
-
Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we …
-
Competing interests T.A.Y. reports consulting fees from 858 Therapeutics, AbbVie, Acrivon, Adagene, Aeneid Therapeutics, Almac, Alterome …
-
From April 2020 to September 2022, 16 patients with unresectable FLC were enrolled (Fig. 1a). The …
-
RESEARCH HIGHLIGHT 14 November 2025 Adjuvant atezolizumab improved survival outcomes in patients with muscle-invasive bladder cancer …
-
Trial design Table of Contents Trial design Patient and tumor characteristics Pathological response Safety Tumor subgroups …
-
Inclusion and ethics Table of Contents Inclusion and ethics Study design, population and inclusion/exclusion criteria MTB …
-
Study design, baseline clinicopathological characteristics and demographics Table of Contents Study design, baseline clinicopathological characteristics and …
- 1
- 2